Clinical trial
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
NCT02067143 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 20, 2014
- Completion date
- December 7, 2020
- Enrollment
- 204 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.
de novo, low-dose corticosteroids pretreatment, secondary, untreated philadelphia positive acute lymphoblastic leukemia